About this medicine

Lunivia is a prescription treatment for severe, disabling or very distressing insomnia in adults. Assessment should also look for physical illness, depression, other medicines and sleep habits contributing to sleeplessness.

What is this medicine used for?

The UK indication is adult insomnia, usually for short periods. The licence is not a treatment recommendation for every person with poor sleep and does not establish local NHS funding.

Which warning signs need help?

Sleep-walking, sleep-driving or other activities without awareness need urgent clinical review and no further dose until advised. Slow breathing, severe allergy or overdose need emergency assessment. Avoid driving or hazardous tasks particularly within 12 hours after a dose.

New hallucinations, marked behavioural change or worsening depression need prompt clinical review. Seek urgent help for self-harm thoughts or immediate danger; a sleeping medicine does not treat the underlying depression.

How do I take it safely?

The adult reference starting dose is 1 mg at bedtime; clinicians may increase it to a maximum 3 mg. Usually treatment, including tapering, is no longer than four weeks; extension needs reassessment. The maximum for older adults is 2 mg.

Plan a full night's sleep; take only one dose at bedtime. Selected chronic-insomnia treatment can extend to six months only with repeated benefit–risk review, not automatic repeats. A higher tablet strength does not itself justify longer treatment.

The UK product ceiling is also 2 mg in severe kidney impairment; severe liver insufficiency is a contraindication, not a reason to reuse the US liver-disease dose rule. Dose selection needs the actual UK product information and clinical review.

What side effects should I know about?

An unpleasant taste is particularly recognised. Headache, dizziness, dry mouth, nausea and sleepiness can also occur. Report persistent symptoms instead of increasing the dose yourself.

Who needs extra care with this medicine?

The product excludes severe sleep apnoea, severe respiratory or liver failure, myasthenia gravis and previous complex sleep behaviour with hypnotics. Depression and substance-use history require careful assessment.

Can it affect my other medicines?

Alcohol, opioids and other sedatives can dangerously compound sedation and breathing suppression. Strong CYP3A4 inhibitors increase exposure; in older adults that combination is contraindicated.

For other adults taking a potent CYP3A4 inhibitor, the ceiling is 2 mg. An inhibitor raises exposure while an inducer may lower it; starting or stopping another medicine calls for review rather than guessing a replacement dose.

What check-ups will I need?

Review benefit, next-day functioning, unusual night-time behaviours and continuing need. Agree a stopping strategy before starting; lack of improvement after 7–14 days warrants reassessment of the cause.

What about pregnancy, breastfeeding and age?

It is not for under-18s. Pregnancy is not recommended and the product should not be used while breastfeeding. Discuss pregnancy plans and any accidental exposure with the prescriber.

What if I miss a dose or want to stop?

Do not take an extra dose later in the same night. Dependence and withdrawal can develop; agree an individual reduction plan rather than abruptly stopping regular treatment.

How does it work?

Eszopiclone’s sleep-promoting effect is thought to involve GABA, a chemical messenger that helps restrain nerve-cell activity. It acts at receiving structures associated with this messenger, although the precise steps that produce sleep are not fully understood. Its effects can include both sleepiness and reduced alertness after waking.

How Brain Cells Communicate

Brain cells use chemical messages to influence whether neighboring cells send electrical signals. GABA is one of the main inhibitory messengers, meaning it generally makes further activity less likely. It acts through receptor complexes, groups of proteins that receive the message and change the cell’s response. These connections participate in sleep as well as memory, movement and attention.

What is known: Inhibitory signaling is a normal part of how brain networks regulate activity.

What remains uncertain: Insomnia does not point to a single faulty GABA receptor or a measurable shortage of GABA.

GABA-A signaling

A GABA-A channel with ochre GABA symbols at outer sites and lavender chloride ions in an open pore. Chloride · Cl−: Inward movement is a typical mature-cell example; ion gradients can differ. GABA-A receptor / channel: GABA activates this ion channel. Open channel: The arrow shows a qualitative direction, not an ion count or measured rate.

Optional motion shows inward ion movement in this example. Counts and timing are illustrative.

  1. Chloride · Cl−

    Inward movement is a typical mature-cell example; ion gradients can differ.

  2. GABA-A receptor / channel

    GABA activates this ion channel.

  3. Open channel

    The arrow shows a qualitative direction, not an ion count or measured rate.

Simplified teaching model. Protein shapes, sizes, particle counts and arrows are illustrative, not measurements or experimental structures.

GABA-A receptor complexes participate in inhibitory signaling. The chloride direction shown is an illustrative mature-cell example, not a rule for every cell.

Inhibitory signaling is a normal part of how brain networks regulate activity. Simplified illustration of the process; individual responses vary.
About this illustration

GABA signaling; Receptor complex; Neural inhibition. Insomnia does not point to a single faulty GABA receptor or a measurable shortage of GABA.

This is a simplified illustration. It does not show exactly how a medicine fits into a protein or predict a dose or response to treatment.

How the Medication Changes Signaling

The prescribing information links eszopiclone’s effect to sites on GABA receptor complexes that are close to, or connected with, sites used by benzodiazepines, a family of calming medicines. A binding site is a part of a protein where a medicine can attach. Connected sites can influence one another, so attachment at one place may change how another part responds. This provides a plausible explanation for increased inhibition without claiming that every step from binding to sleep has been established.

What is known: Eszopiclone’s action is associated with GABA-related receiving structures.

What remains uncertain: The label does not establish one receptor subtype as the complete explanation for its benefit.

How the process works

  1. Eszopiclone
  2. GABA-related action
  3. Sleep and sedation
Eszopiclone’s action is associated with GABA-related receiving structures. Simplified illustration of the process; individual responses vary.
About this illustration

Eszopiclone; GABA-related action; Sleep and sedation. The label does not establish one receptor subtype as the complete explanation for its benefit.

This is a simplified illustration. It does not show exactly how a medicine fits into a protein or predict a dose or response to treatment.

A Closer Look at the Molecular Level

The liver breaks down eszopiclone using enzymes, proteins that help chemical reactions occur, including CYP3A4 and CYP2E1. Older age, severe liver impairment and certain interacting medicines can increase exposure, the amount present in the body over time. Continued exposure after waking can interfere with reactions or coordination even without a strong feeling of sleepiness.

What is known: Removal of the medicine helps determine how long unwanted effects can persist.

What remains uncertain: A person’s sense of being alert may not match their actual performance.

How the process works

  1. Dose and release
  2. Drug exposure
  3. Next-day function
Removal of the medicine helps determine how long unwanted effects can persist. Simplified illustration of the process; individual responses vary.
About this illustration

Dose and release; Drug exposure; Next-day function. A person’s sense of being alert may not match their actual performance.

This is a simplified illustration. It does not show exactly how a medicine fits into a protein or predict a dose or response to treatment.

How does it affect my body?

Reduced alertness can persist into the following day. Memory disturbance, falls and impaired coordination matter especially in older people; sufficient time in bed does not guarantee safe driving.

How does my body process it?

CYP3A4 and CYP2E1 participate in metabolism. Age, severe kidney impairment, liver disease and enzyme-inhibiting medicines can alter exposure, so the same tablet strength is not appropriate for everybody.

How do treatment options differ?

Lunivia is not a milligram-for-milligram replacement for zopiclone. Similar-sounding names and shared sedative actions do not establish identical dosing or interchangeability.

A closer look at the science

Eszopiclone is a cyclopyrrolone, chemically different from benzodiazepines. Its effects are thought to involve GABA-A receptor complexes; the precise mechanism is not completely established.

Eszopiclone is the S-enantiomer of zopiclone, a cyclopyrrolone-class compound with a single chiral center.

Chemical formula: C17H17ClN6O3

The formula describes the parent compound. The stereochemical bond in the verified structure indicates its S configuration; racemic zopiclone is a different composition and is not an interchangeable name.

Verified PubChem structure of S-configured eszopiclone.
NCBI PubChem CID 969472. Lines are bonds; unlabeled corners are carbon and many hydrogen atoms are omitted. This neutral-parent drawing is connectivity, not a binding pose.

The structure does not establish receptor occupancy, dose equivalence or individual response.

How was this medicine developed?

The 2009 Lunivia centralised European application was withdrawn. Current UK product records checked in 2026 are separate evidence; that old event must not be used to label today's UK product unavailable.

Sources and References

  1. Lunivia 1 mg film-coated tablets: UK SmPC

    Product information published on the electronic Medicines Compendium (emc); supplied by pharmaceutical companies.

    Scope: United Kingdom.

  2. Lunivia 3 mg film-coated tablets: UK SmPC

    Product information published on the electronic Medicines Compendium (emc); supplied by pharmaceutical companies.

    Scope: United Kingdom.

  3. Lunivia: patient leaflet

    Product information published on the electronic Medicines Compendium (emc); supplied by pharmaceutical companies.

    Scope: United Kingdom.

  4. Lunivia: withdrawn application

    Scope: European Union, historical.

  5. Lunivia 2 mg film-coated tablets: UK SmPC

    Product information published on the electronic Medicines Compendium (emc); supplied by pharmaceutical companies.

    Scope: United Kingdom.

  6. Eszopiclone — UK product-information inventory

    Product information published on the electronic Medicines Compendium (emc); supplied by pharmaceutical companies.

    Scope: United Kingdom.

  7. Lunesta: current prescribing information

    Scope: Shared science only; original source jurisdiction retained in title/publisher.

  8. Eszopiclone: MedlinePlus Drug Information — mechanism explanation

    Scope: Mechanism explanation only. Source sections checked: Why is this medication prescribed?; What special precautions should I follow?..

  9. Lunesta: FDA prescribing information

    Scope: Shared science only; original source jurisdiction retained in title/publisher.

  10. Eszopiclone: verified neutral parent, PubChem CID 969472

    Scope: Shared science only; original source jurisdiction retained in title/publisher.

  11. Schizophrenia
  12. NIMH: Understanding psychosis

Shared scientific background. US product pharmacology and international chemical references do not establish UK licences, doses, formulations or NHS recommendations.

Was this article helpful?

Was this article helpful?

Sends your choice, article identifier, edition and optional issue to Psychiatry Atlas. No name, email or medical details are requested. Daily network codes help prevent spam; hosting may process technical information. This is not a promise of anonymity. Privacy details.

Enable JavaScript to send feedback.

Suggest a missing topic or describe a correction. Please keep personal medical information out of website feedback.

Back to top